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Abstract Breast cancer is one of the leading causes of
cancer-related deaths in women. Regardless of prognosis,
all women with breast cancer are at risk for early
recurrence. Nearly 50% of early recurrences occur within
5 years of surgery, and they peak at 2 years after surgery in
women treated with adjuvant tamoxifen. Most early
recurrences are distant metastases, which strongly correlate
with increased mortality. Treatments that mitigate the risk
of early distant metastases (DM) are, therefore, likely to
improve overall survival in women with early breast cancer
(EBC). Aromatase inhibitors (AIs)—anastrozole, letrozole,
and exemestane—have been investigated as alternatives to
tamoxifen for adjuvant treatment of hormone receptor-
positive (HR+) EBC in postmenopausal women (PMW).
AIs are better at minimizing risk of early relapse compared
with tamoxifen. However, it is not clear if preferential use
of AIs over tamoxifen will benefit all PMW with HR+
EBC. The ability to subtype HR+ breast cancer on the basis
of biomarkers predictive of response to AIs and tamoxifen
would likely be key to determining the most beneficial
hormonal treatment within patient subpopulations, but this
process requires thorough investigation. Until then, adju-
vant therapies that provide the greatest reduction in risk of
DM should be considered for all PMW with HR+ EBC.
This article reviews the clinical trials of AI adjuvant
therapies for hormone-sensitive breast cancer, particularly
in the context of how they compare with tamoxifen in
minimizing the risk of relapse, occurrence of DM, and
breast cancer-related deaths.
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1 Introduction
Breast cancer is the most frequently diagnosed cancer in
women and the second leading cause of cancer-related
death in women. In the USA alone, an estimated 192,370
new cases of invasive breast cancer with roughly 40,170
breast cancer deaths were expected to occur in 2009 [1].
Over two thirds of breast cancers are hormone-sensitive and
thus candidates for endocrine therapy. Endocrine therapy
removes estrogen from the body or inhibits estrogen from
binding to cancer cells and is the principal adjuvant
treatment given to postmenopausal women (PMW) with
hormone receptor-positive (HR+) early breast cancer (EBC)
in an attempt to minimize the risk of relapse. The risk of
relapse, which is greatest during the first 5 years of surgery,
peaks at approximately 2 years [2–4]. At this peak, distant
metastases (DM) are the most common type of recurrence,
compared with locoregional or contralateral recurrences
[4, 5].
DM comprise between 50% and 75% of all early
recurrences [3, 5, 6], and their appearance is the harbinger
of breast cancer-related death. The 5-year survival rate for
patients with DM is much lower than for patients with
locoregional, contralateral, and no recurrence [5]. There-
fore, reducing the risk of DM is an important therapeutic
goal [5, 7–10]. Adjuvant endocrine therapies that are most
effective in reducing the risk of DM may have the most
favorable impact on survival in PMW with EBC. For over
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DOI 10.1007/s10555-010-9248-xtwo decades, tamoxifen was thought to be the optimal
adjuvant therapy for PMW with HR+ EBC. Recent studies
have challenged that notion, leading to the consideration of
the aromatase inhibitors (AIs) anastrozole, letrozole, and
exemestane as alternatives to tamoxifen [11–16].
Until recently, the use of upfront monotherapy with an
AI (i.e., instead of tamoxifen) versus a sequential/switch
strategy (i.e., after some period of initial tamoxifen) was a
matter of considerable debate. However, the importance of
upfront AI therapy is now widely recognized, particularly
in patients at higher risk of early relapse [17]. Indeed,
recent data from the Breast International Group (BIG) 1-98
trial comparing a sequential strategy with tamoxifen
followed by an AI (letrozole) with AI monotherapy has
demonstrated that sequencing is not superior to monother-
apy with an AI (letrozole) alone [16]. Major clinical trials
of adjuvant therapies for hormone-sensitive breast cancer,
which compare the efficacy and safety of AIs with that of
tamoxifen in minimizing the risk of recurrence, DM, and
breast cancer-related deaths, are discussed below.
2 Risk of early relapse and distant metastasis
All patients with breast cancer are at risk for early relapse.
The risk of recurrence is greatest during the first few years
following surgery [2–4, 6]. In a recent retrospective
analysis of 3,614 PMW with estrogen receptor-positive
(ER+) EBC who were treated with tamoxifen following
surgery, the annual recurrence rate overall was 4.3%, and
most of these (3.4%) were DM [4] (Fig. 1). Locoregional
and contralateral recurrences did not exceed 1% at any time
during the study. During the 5-year median follow-up of
this patient cohort, 476 developed recurrences, and of these,
344 were DM. Patients with DM had the poorest outcomes:
50% died within 0.65 years (7.8 months) from the time of
DM and 75.6% (260/344) died overall [8]. Lamerato et al.
have consistently reported DM to be the most common site
of recurrence (58.3%), with only 26.1% of recurrences
locoregional, and 15.6% contralateral [5]. The 5-year
probability of overall survival (OS) was poorest for women
with DM (41.3%) compared with those with locoregional
(59.3%), contralateral (83.4%), or no recurrence (91.7%)
[5].
Factors predictive of early recurrence include hormone
receptor (ER and/or progesterone receptor (PgR)) status,
degree of nodal involvement, and tumor size and tumor
grade [4, 6, 18]. Patients who have tumors involving >3
nodes, tumors >5 cm, or grade III tumors and who are
receiving adjuvant tamoxifen have about a three-fold
increase in risk of recurrence (all P<0.001) [4]. However,
individual risk factors such as node-negative (N−) status
must be considered along with other factors. For example,
according to the St. Gallen risk classification, patients with
N− tumors that are large (>2 cm), high-grade (histologic
and/or nuclear grades 2 and 3), or show evidence of
peritumoral vascular invasion are considered intermediate
risk [19]. It should be noted, however, that while these
factors help assess the overall risk for early recurrence, they
are not taken into account when determining the treatment
strategy, as almost all tumors that show evidence of
endocrine responsiveness (i.e., the presence of any ER)
are considered candidates for endocrine therapy [17].
Recent evidence suggests that Ki67 labeling index (LI),
a measure of tumor proliferative capacity, could identify
patients at increased risk for poor outcomes within the St.
Gallen risk classification and Adjuvant! Online risk
categories [20]. Specifically, those with high Ki67 LI
(≥10%) had significantly poorer disease-free survival
(DFS) in both the intermediate (91.9% vs. 86.3%; P=
0.01) and high-risk groups (82.5% vs. 61.4%; P=0.01) of
St. Gallen 2007, compared with those with low Ki67 LI
[20].
The potential utility of gene expression profiles [21]i n
the accurate prediction of risk recurrence and treatment
response is also being explored. The prognostic and
predictive value of the Oncotype DX recurrence score
assay using the 21-gene tumor signature has been validated
in ER+, N− patients receiving tamoxifen [22, 23]. The
phase 3 Trial Assigning Individualized Options for Treat-
ment was designed to determine the best individualized
treatment for PMW with ER+, N− breast cancer, with a
recurrence score of 11–25 [24]. The value of the Oncotype
DX recurrence score has been recently investigated in
major clinical trials of AIs. Recent results of the Trans
Arimidex, Tamoxifen Alone or in Combination (ATAC)
trial indicate that Oncotype DX is an independent predictor
of risk of DM in N− and N+, HR+ patients; however, the
data were not predictive of a differential benefit between
anastrozole and tamoxifen [25]. A prospectively controlled
study of 6,000 women with N− breast cancer (microarray in
node-negative and one to three positive-lymph node-disease
Fig. 1 Prevalence of distant metastases at 2-year peak of overall
recurrences [4]
582 Cancer Metastasis Rev (2010) 29:581–594may avoid chemotherapy) compares a 70-gene expression
signature (Mammaprint) with common clinical–pathologi-
cal criteria to select patients for adjuvant chemotherapy
[26].
Thus, although several clinical and molecular prognostic
factors for early risk of DM are known, the ability to
accurately predict a favorable response to a particular
adjuvant therapy remains elusive. Advanced methods of
individual risk assessment must be rigorously validated
before treatment strategies can be tailored to a patient’s
unique molecular profile. Until then, all PMW with HR+
EBC should be considered at risk for recurrence and
candidates for adjuvant endocrine therapy, to minimize the
risk of DM and improve the chances of survival [17].
3 Adjuvant tamoxifen therapy and impact on DM
Until recently, on the basis of previous clinical trial results
[27], 5 years of tamoxifen was the standard adjuvant
treatment for PMW with HR+ EBC. Meta-analysis of the
Early Breast Cancer Trialists’ Collaborative Group
(EBCTCG) showed that, at a median follow-up of 15 years,
5 years of adjuvant tamoxifen therapy significantly reduced
recurrence risk by 41% and mortality by 34% in patients
with ER+ tumors compared with placebo. Adjuvant
tamoxifen therapy reduced the risk of local recurrences by
53% (hazard ratio (HR)=0.47; P<0.00001) and the risk of
DM by 36% (HR=0.64; P<0.00001) [27, 28]. Despite
these findings, many patients receiving tamoxifen continue
to experience recurrences, 50% of which occur within the
first 2 to 3 years after surgery, a period when DMs comprise
between 50% and 75% of recurrences [3, 4, 6].
Trials such as the National Surgical Adjuvant Breast and
Bowel Project (NSABP) B-14 study and the Stockholm
Tamoxifen trial indicate that tamoxifen therapy reduces the
risk of recurrence, but primarily for locoregional recurren-
ces and not the more serious and life-threatening DM [29,
30]. Also, recent studies have demonstrated that PMW with
ER+ EBC who are homozygous for variant alleles of
cytochrome P (CYP) 2D6 are unable to metabolize
tamoxifen effectively [31, 32]. Consistently, women receiv-
ing tamoxifen in combination with a CYP2D6 inhibitor
display an increased risk for breast cancer recurrence
compared with those receiving tamoxifen alone (2-year
recurrence 13.9% vs. 7.5%; HR=1.92; P<0.001) [33].
These findings led the Food and Drug Administration to
recommend relabeling tamoxifen to reflect the possible
negative effects on outcomes in women may have reduced
CYP2D6 activity. In addition, because of its estrogen-
agonistic activity in selected tissues, tamoxifen is associated
with serious adverse events (SAEs) such as endometrial
cancer and thromboembolic events [34].
4 AIs and treatment strategy trials
Third-generation AIs include anastrozole, letrozole, and
exemestane. Anastrozole and letrozole are nonsteroidal
drugs that block estrogen synthesis through a competitive
inhibition of aromatase, while exemestane is a steroidal AI
that blocks estrogen synthesis by irreversibly binding with
aromatase and inhibiting its activity [35]. All three AIs
almost completely block estrogen synthesis and have been
approved by the Food and Drug Administration for the
treatment of early-stage breast cancer because of their
efficacy and tolerability in a variety of clinical settings [36].
However, there is evidence that letrozole provides a greater
suppression of both plasma (residual estradiol (after 6 weeks
of AI therapy): 4.8% letrozole vs. 7.2% anastrozole, P=
0.018; residual estrone: 1.2% letrozole vs. 3.7% anastro-
zole, P=0.003; residual estrone sulfate: 1.1% letrozole vs.
4.7% anastrozole, P=0.003) and tissue (residual estradiol
(after 16 weeks of AI therapy): 2.4% letrozole vs. 11.0%
anastrozole, P=not reported (NR); residual estrone: 9.3%
letrozole vs. 16.6% anastrozole, P=NR; residual estrone
sulfate: 9.9% letrozole vs. 27.1% anastrozole, P=NR)
estrogen levels compared with anastrozole [37]. Clinical
trials of adjuvant AIs in PMW with HR+ breast cancer
include initial adjuvant, extended adjuvant, switch, and
sequential trials (Fig. 2).
Upfront adjuvant trials—the ATAC trial, BIG 1-98
(monotherapy arms), and tamoxifen exemestane adjuvant
multicenter (TEAM) trials—randomized newly diagnosed
patients immediately following surgery and administered
5 years of treatment with either tamoxifen, an AI, or a
sequence of tamoxifen and AI [11, 12, 15, 16, 38, 39]. The
TEAM trial was designed to compare tamoxifen with the
Fig. 2 Types of adjuvant trials. AI aromatase inhibitor
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[39]; the trial was amended to compare exemestane with
sequential use of tamoxifen to exemestane at 5 years
(second primary endpoint) [40].
Switch adjuvant AI trials, such as the Intergroup
Exemestane Study (IES), Italian Tamoxifen Anastrozole
(ITA) trial, the Austrian Breast and Colorectal Study Group
8 (ABCSG 8), and ARimidex NOlvadex (ARNO) 95 trials
randomized disease-free patients who received 2 to 3 years
of adjuvant therapy with tamoxifen as part of a 5-year
course and compared the relative efficacy of continuing
their treatment with tamoxifen or switching to an AI [14,
41–43]. Only patients who are disease-free at the time of
randomization are allowed to continue in switch trials,
excluding patients whose disease recurs during the first 2 to
3 years of tamoxifen therapy. This is different from
sequential adjuvant trials (BIG 1-98 sequential arms and
TEAM), which include all recurrences after randomization
in their efficacy analysis, including events during the early
peak at 2 to 3 years [2, 4]. Thus, while sequential trials are
designed to assess the benefit of sequential therapy versus
monotherapy in newly diagnosed patients, switch trials
primarily address whether the risk of an event beyond
2 years is reduced by switching to an AI.
Lastly, extended adjuvant trials, such as the National
Cancer Institute of Canada MA.17 Trial, ABCSG 6, and the
NSABP B-33 trial, are designed to evaluate the benefit of
additional endocrine therapy by randomizing patients who
have already received a standard 5-year course of tamoxifen
to further treatment with an AI or placebo (or no treatment
in the case of the open-label ABCSG-6A trial) [44–47]. The
different strategies that have been examined (Fig. 2) across
multiple AI trials thus provide a number of treatment
options for endocrine therapy in PMW with EBC.
5 Upfront AI therapy and impact on DM
5.1 ATAC: upfront therapy with anastrozole
This was a large, double-blind, randomized, non-inferiority/
superiority comparison of anastrozole (n=3,125) with
tamoxifen (n=3,116) or a combination of anastrozole and
tamoxifen (n=3,125) for 5 years in PMW with EBC. The
combination arm was discontinued after the initial analysis
for lack of efficacy; thus, a third of the trial participants
were lost [12, 38]. Importantly, because the trial was
designed and implemented soon after the initial introduc-
tion of AIs as adjuvant therapy, the population was not
restricted to patients with HR+ disease [38] but also
included patients with HR-unknown tumors (16.3% of the
total trial population). Subsequent analyses have thus
focused on the comparison of anastrozole with tamoxifen
in both the intent-to-treat (ITT) population and the more
relevant subgroup of HR+ patients (n=5,216 of the original
9,366) [12, 15]. At a median follow-up of 33.3 months,
anastrozole demonstrated significantly better DFS com-
pared with tamoxifen (HR=0.87; P=0.005) and with the
combination of anastrozole and tamoxifen (HR=0.76;
P=0.002). Time to recurrence (TTR) was significantly
longer in the anastrozole group than in the tamoxifen group
(HR=0.73, P=0.003), but there was no significant differ-
ence between tamoxifen and the combination groups (HR=
1.09; P=0.4). These initial results do not provide informa-
tion on DM rates and survival, because this was an event-
driven analysis requiring at least 704 distant recurrences,
and only 615 were recorded [38].
At a median of 68 months of follow-up, DFS was
significantly better with anastrozole versus tamoxifen in
HR+ patients (HR=0.83; P=0.005), as was TTR
(HR=0.74; P=0.0002), but time to distant recurrence
(TTDR) was not significantly different between
anastrozole- and tamoxifen-treated groups in the HR+
population (HR=0.84; P=0.06; Table 1)[ 12]. Findings at
the 100-month follow-up also demonstrated that anastro-
zole was superior to tamoxifen in improving DFS (HR=
0.85; P=0.003) and TTR (HR=0.76; P=0.0001), with a
particular benefit in locoregional and contralateral breast
cancer recurrence. At this follow-up post treatment, there
were 16% fewer DM in the HR+ population (HR=0.84; P=
0.022; 305 anastrozole vs. 357 tamoxifen events) [15].
However, it is important to note that significant improve-
ment in TTDR was achieved post-treatment only after a
median follow-up of 100 months [15].
Disappointingly, while anastrozole appeared to provide
significant benefit with the improvement in DFS, no
improvement was seen in survival with more than 9 years
of follow-up. OS (HR=0.97; P=0.7; 472 anastrozole vs.
477 tamoxifen deaths), deaths after recurrence (HR=0.90;
P=0.2; 245 anastrozole vs. 269 tamoxifen deaths), and
deaths without recurrence (HR=1.05; P=0.6; 227 anastro-
zole vs. 208 tamoxifen deaths) were not significantly
different between the two groups [15]. A retrospective
analysis of ATAC at 2.5 years, undertaken to better
understand the types of early recurrences in the ITT
population, indicated fewer locoregional, DM, and contra-
lateral recurrences with anastrozole compared with tamox-
ifen, but the greatest benefit with anastrozole was in
reducing the risk of locoregional and contralateral events
with less impact on DM (7% reduction; Fig. 3)[ 3]. A
recently reported retrospective analysis of events at 2 years
in the HR+ population of ATAC also reported fewer overall
recurrences with anastrozole relative to tamoxifen, but the
reduction in DM was not significant (HR=0.79; 95% CI,
0.58–1.07) [48]. The AEs profile of ATAC displayed a
greater incidence of fractures (11% anastrozole vs. 7.7%
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vs. 29.4% tamoxifen; P<0.0001) in anastrozole-treated
women in contrast to a greater incidence of endometrial
cancer (0.2% anastrozole vs. 0.8% tamoxifen; P=0.02),
venous thromboembolic events (2.8% anastrozole vs. 4.5%
tamoxifen; P=0.0004), and gynecologic abnormalities (i.e.,
vaginal bleeding, discharge, hot flushes; all P<0.0001) in
tamoxifen-treated women [12].
5.2 BIG 1-98: upfront therapy with letrozole
This large, double-blind, randomized, superiority trial was
designed and implemented by the IBCSG to evaluate the
efficacy of letrozole versus tamoxifen monotherapy, or
letrozole and tamoxifen as sequential therapy, in either
order, compared with letrozole alone as initial adjuvant
endocrine therapy, in PMW with EBC (N=8,010). BIG 1-
98 was comprised of a four-arm option which assigned
patients to 5 years of letrozole (n=1,546); 5 years of
tamoxifen (n=1,548); 3 years of tamoxifen after 2 years of
letrozole (n=1,540); and 3 years of letrozole after 2 years of
tamoxifen (n=1,548), and a two-arm option, which
assigned patients to 5 years of letrozole (n=917) or
tamoxifen (n=911) therapy [11].
The BIG 1-98 trial is uniquely designed to study two key
questions regarding the use of AIs and tamoxifen: 1) the
efficacy of letrozole monotherapy versus tamoxifen mono-
therapy [11, 16, 49] and 2) whether sequential therapy, in
either order, is superior to monotherapy [16]. Unlike the
ATAC trial, BIG 1-98 required patients’ tumors to be HR+,
defined as positive for ER, PgR, or both [11]. The first
report from BIG 1-98 (N=8,010), the primary core analysis
(PCA), was designed to compare letrozole and tamoxifen as
initial adjuvant therapy. The PCA included events from the
Initial adjuvant trials Endpoint F/U (months) HR for recurrence P value
BIG 1-98 (letrozole) TTDR 25.8 (PCA) 0.73
a 0.001
76 (MAA) 0.85
a 0.05
DFS 25.8 (PCA) 0.81
a 0.003
76 (MAA) 0.88
a 0.03
OS 25.8 (PCA) 0.86
a 0.16
76 (MAA) 0.87
a 0.08
ATAC (anastrozole) TTR 68 0.74
b 0.0002
100 0.76
b 0.0001
TTDR 68 0.84
b 0.06
100 0.84
b 0.022
DFS 68 0.83
b 0.01
100 0.85
b 0.003
OS 68 0.97
b 0.7
100 0.97
b 0.7
Table 1 Efficacy end points
from upfront adjuvant trials
comparing tamoxifen and
aromatase inhibitors
Source: [11, 12, 15, 16]
ATAC arimidex, tamoxifen
alone or in combination, BIG
Breast International Group,
DFS disease-free survival, HR
hazard ratio, OS overall
survival, MAA monotherapy
arm analysis, PCA primary
core analysis, TTDR
time to distant recurrence,
TTR time to recurrence
aITT population
bHR+ population
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Fig. 3 Absolute reduction in overall recurrences and distant metas-
tases in the a Arimidex, Tamoxifen Alone, or Combination trial
(hormone receptor-positive patients) at 2.5 years [3] and b Breast
International Group 1-98 at 2 years [6]. ANA anastrozole; LET
letrozole; TAM tamoxifen
Cancer Metastasis Rev (2010) 29:581–594 585four- and two-arm option, including events from the initial
treatment period of the two sequential arms up to 30 days
after the switch, thus increasing the statistical power of the
comparison (Fig. 4).
At a median follow-up of 25.8 months, the PCA
demonstrated that letrozole treatment significantly improved
DFS (HR=0.81; P=0.003; 351 letrozole vs. 428 tamoxifen
events) and TTR (HR=0.72; P<0.001) and produced a
significant 27% reduction in the risk of DM (TTDR)
compared with tamoxifen (HR=0.73; P=0.001; 184
letrozole vs. 249 tamoxifen events). OS did not reach
statistical significance at this early follow-up (HR=0.86;
P=0.16; 166 letrozole vs. 192 tamoxifen events; Table 1)
[11]. A retrospective analysis examining the predictors of
early relapse in BIG 1-98 (N=7,707) at 2 years found that
letrozole reduced the risk of both overall recurrence and DM
(87 letrozole vs. 125 tamoxifen events) by 30% (Fig. 3)[ 6].
This is particularly important given the preponderance of
DM at this time point [4] and the impact of DM on survival
[5, 8]. Based on the 2005 PCA results and the superiority of
letrozole over tamoxifen, the IBCSG decided to unblind
the tamoxifen monotherapy arm and allow patients to cross
over to the letrozole arm. The other three arms remained
blinded [16].
Upon being counseled regarding the superiority of
letrozole versus tamoxifen, 619 patients (25.2%) on
tamoxifen monotherapy chose to cross over to letrozole;
most did so in 3–5 years and received letrozole for a
median of 18 months. Subsequent analyses of the PCA
(60.5 months), and the analysis of the monotherapy arms
(MAA) at 76 months, were affected by this crossover of
patients who were at high risk for recurrence, most likely in
favor of those in the tamoxifen arm, who benefited by the
early switch to letrozole. Therefore, data were presented as
protocol-defined ITT population (including crossover
patients) and a second analysis that censored patients at
the time of crossover. At a median follow-up of 76 months,
an analysis of the ITT population in the MAA demonstrated
consistent benefit, with a significant improvement in DFS
(HR=0.88; 95% CI, 0.78–0.99; P=0.03) and TTDR (HR=
0.85; 95% CI, 0.72–1.00; P=0.05) with letrozole [16].
Letrozole also demonstrated a strong trend, despite the
crossover, for improved OS (303 letrozole vs. 343
tamoxifen events; HR=0.87; 95% CI, 0.75–1.02; P=
0.08). In the censored analysis, results demonstrated even
greater benefit with letrozole. Patients receiving letrozole
had significant improvements in DFS (HR=0.84; 95% CI,
0.74–0.95), TTDR (HR=0.81; 95% CI, 0.68–0.96), and OS
(HR=0.81; 95% CI, 0.69–0.94).
There were 40 fewer deaths in the letrozole groups
compared with the tamoxifen group (303 vs. 343) and an
identical number of non-breast cancer-related deaths in each
group (87 vs. 87), indicating that the OS benefit provided
by letrozole is due to improved cancer survival. Consistent
with the findings of the MAA at 76 months’ median follow-
up, the 60.5 months’ median follow-up of the ITT
population in the PCA also found a benefit in DFS (HR=
0.86; 95% CI, 0.77–0.96; P=0.008), TTR (HR=0.82; 95%
CI, 0.71–0.95; P=0.004), and TTDR (HR=0.79; 95% CI,
0.68–0.92; P=0.003). There was also a trend toward
improved OS with letrozole (HR=0.87; 95% CI, 0.75–
1.01; P=0.07) [49]. In the censored analysis, patients
receiving letrozole demonstrated significant benefits in
DFS (HR=0.83; 95% CI, 0.74–0.93), TTR (HR=0.79;
95% CI, 0.68–0.90), and TTDR (HR=0.78; 95% CI, 0.67–
0.92). Importantly, there was a significant benefit in OS
(HR=0.81; 95% CI, 0.70–0.94) [49]. However, the IBCSG
concluded that early crossover to letrozole, although ethical
Fig. 4 Breast International
Group 1-98 schema/analysis.
CT chemotherapy; ITT intent-to-
treat
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likely biased the ITT analysis in favor of tamoxifen and the
censored analysis in favor of letrozole, and makes accurate
assessments of OS difficult. Therefore, to adjust for the
potential bias due to crossover, an additional Inverse
Probability of Censoring Weighted (IPCW) analysis [50]
was undertaken to provide a more accurate estimate of the
clinical benefit of letrozole. The results of the analysis not
only underscored the importance of validated methods,
such as the IPCW analysis, but also unequivocally
demonstrated that 5 years of letrozole significantly
improved DFS by 15% (HR=0.85; 95% CI, 0.76–0.96)
and OS by 17% (HR=0.83; 95% CI, 0.7–0.97) [51], and
reflected the statistics that might have been observed in the
absence of selective crossover [16].
The 60.5-month update of the PCA population corrob-
orates findings of the 76-month monotherapy analysis
showing an emergent benefit of letrozole on survival with
long-term follow-up [16]. The survival benefit with
letrozole, not evident when anastrozole was compared with
tamoxifen in the ATAC trial, underscores the substantial
benefit realized when early DM are controlled, as illustrated
by the PCA and the retrospective analysis examining the
predictors of early relapse at 2 years [6, 11]. This is the first
time an upfront adjuvant trial has demonstrated improve-
ment in OS, and it provides further evidence that preventing
early DM translates into a long-term survival advantage.
Findings from the safety analysis reported with the 60.5-
month update of the PCA population were consistent with
those of the initial PCA analysis, and with known AEs of
letrozole and tamoxifen, without evidence of risk increasing
over time [49].
5.3 FACE: upfront therapy—letrozole versus anastrozole
The randomized, open-label Femara Anastrazole Clinical
Evaluation (FACE) trial was designed to compare the safety
and efficacy of anastrozole versus letrozole in the upfront
AI treatment of PMW with HR+ and N+ breast cancer [52,
53]. The primary outcome measures are rate of DFS at
5 years between letrozole and anastrozole; secondary
outcome measures include safety, efficacy, OS, and time
to DM [52, 53]. Although results from the ATAC and BIG
1-98 trials allow for indirect comparisons, forthcoming
results from FACE should determine conclusively whether
any important efficacy differences exist between these two
nonsteroidal AIs.
5.4 TEAM: upfront therapy with exemestane
In this randomized, multinational, open-label study of
PMW with HR+ EBC (N=9,300), investigators in nine
countries followed nearly identical protocols, with minor
differences based on local guidelines [54]. The trial was
originally designed to evaluate the efficacy and safety of
5 years of initial monotherapy with exemestane or
tamoxifen. However, based on the initial results of the
IES [41], the design was amended; women randomized to
tamoxifen had to switch after 2.5–3 years to exemestane for
the remainder of the 5 years. Therefore, the final design
compared exemestane monotherapy with sequential tamox-
ifen to exemestane therapy for 5 years and compared
exemestane monotherapy with tamoxifen monotherapy at
2.75 years. At 2.75 years, there was no statistically
significant difference in DFS with tamoxifen versus
exemestane monotherapy (HR=0.89; P=0.12), although
improvement in the secondary endpoint of time to DM was
observed (HR=0.81; P<0.03) [39]. As this was time-driven
rather than an event-driven analysis, the primary efficacy
results may have been affected by the high rates of
discontinuation while on tamoxifen monotherapy and the
timing of the exemestane switch [39]. The analysis is
complicated by the fact that almost 30% and 20% of
patients randomized to tamoxifen and exemestane, respec-
tively, discontinued their assigned drug before a protocol-
amended crossover of all participants at 2.75 years.
6 Switch and sequence AI therapy
6.1 Switch study design
In this study design, patients who have already received
between 2 and 3 years of tamoxifen and have remained
disease-free are randomized to either continue tamoxifen or
switch to an AI. The population differs from that of an
initial adjuvant trial such as ATAC or BIG 1-98, which
randomizes patients at the time of surgery. Because patients
have already shown a favorable response to endocrine
therapy, they may be expected to have a better prognosis. In
addition, by definition, the switch design excludes patients
whose disease recurs early (i.e., within 2 years) while on
tamoxifen, including those at risk for early DM [4]. The
IES examined a switch to exemestane [14, 41], whereas the
ARNO 95, ITA, and ABCSG 8 studies examined a switch
to anastrozole versus continued tamoxifen [43, 55].
Combined results of smaller trials (i.e., ARNO 95/ABCSG
8/ITA) as well as the larger IES results are outlined below.
6.2 IES: switching from tamoxifen to exemestane
In this double-blind study, patients (N=4,742) with ER+ or
ER-unknown breast cancer who tolerated 2 to 3 years of
tamoxifen without relapse were randomized to either switch
to exemestane or continue with tamoxifen for the remainder
of 5 years [14, 41]. The study thus excluded patients who
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patients at less risk of relapse or who are more sensitive to
hormonal therapy. Since patients had ER+ or unknown
disease, the ITT analysis includes patients who were later
found to have ER− disease. The population differs from
that of BIG 1-98, which included HR+ patients as defined
by positivity for ER, PgR, or both [11, 14].
At a follow-up of 55.7 months, in the most clinically
relevant ER+/unknown group, there was a significant
improvement in DFS among patients who switched to
exemestane (HR=0.75; P=0.0001) compared with those
who remained on tamoxifen. The risk of DM (TTDR) was
also significantly reduced in exemestane-treated patients in
the ER+/unknown group (HR=0.83; P=0.03). There were
210 deaths in the exemestane group, versus 251 in the
tamoxifen group (17% relative reduction; P=0.05) [14].
Following adjustment for hormone receptor status, there was
a significant OS benefit in the ER+/unknown group [14]. In
the ITT population, 39 deaths were prevented by switching
to exemestane, with 15 fewer deaths related to breast cancer
(151 exemestane vs. 166 tamoxifen) [14]. Similarly, an
updated survival and safety analysis at a median of
91 months of follow-up when at least 91% of surviving
patients had a minimum of 6 years follow-up available
demonstrated continuing improvement in OS with 352
deaths occurring in the exemestane group compared with
405 deaths in the tamoxifen group (HR=0.86; P=0.04)[56].
6.3 ABCSG 8/ARNO 95/ITA
A combined analysis of the similarly designed ABCSG
8 and ARNO 95 trials at 28 months of follow-up reported a
significant benefit in event-free survival (EFS; HR=0.60; P
=0.0009) and in DM-free survival (HR=0.61; P=0.0067)
for patients who switched to anastrozole after 2 years on
tamoxifen relative to those who continued on tamoxifen
[42]. However, there was no significant benefit in OS (97%
switch to anastrozole vs. 96% tamoxifen alone; P=0.16)
[42]. Similarly, a meta-analysis of ABCSG 8, ARNO 95,
and ITA showed significant improvement in DFS (HR=
0.59; P<0.0001), EFS (HR=0.55; P<0.0001), DM-free
survival (HR=0.61; P=0.002), and OS (HR=0.71; P=0.04)
[57], although differences in trial designs and patient
populations warrant a cautious interpretation of results.
The individual results of ARNO 95 (for DFS, HR=0.66; P
=0.049) [55], ABCSG 8 (for EFS, HR=0.68; P=0.02) [58],
and ITA (for DFS, HR=0.35; P=0.001) also support a
switch to anastrozole following 2 years of prior tamoxifen.
Again, although these trials show a significant DFS benefit
in switching patients from tamoxifen to anastrozole or
exemestane, it is not possible to directly compare outcomes
of upfront or switch trials because of differences in the trial
designs and populations analyzed.
6.4 ABCSG 8 trial: sequential therapy with tamoxifen
to anastrozole
This open-label trial examined the efficacy of initial tamox-
ifen therapy followed by a switch to anastrozole after 2 years
compared with tamoxifen monotherapy in patients with
hormone-sensitive breast cancer [42]. ABCSG 8 differed
from other sequential trials in that it randomized newly
diagnosed patients rather than randomizing at the point of
switch [58], allowing a more appropriate analysis of all
events from the time of randomization and not just from the
time of the switch. Notably, when including all events from
randomization at a median of 55 months, the reduction in
risk of recurrence (HR=0.76; P=0.07) achieved by switch-
ing to anastrozole was not significant [59]. In an updated
analysis (median 72 months) for relapse-free survival (RFS)
in the sequence sample (N=2,922), there was a 21%
improvement with the switch to anastrozole (HR=0.79; P=
0.038) [59]. While these data, like the IES data, support the
contention that switching to an AI after 2 years is superior to
continuing tamoxifen, the trial is limited by its open-label
design, and the updated results are complicated by crossover
of patients from tamoxifen to anastrozole (N=82) and
withdrawals during the tamoxifen therapy period. Further-
more, while primary endpoints for the 55-month analysis
looked at EFS but not death from other causes, the 72-month
analysis included both RFS and death from other causes,
making a putative benefit difficult to extrapolate [59]. It is
also noteworthy that although the trial population was at low
to intermediate risk with ductal G1/2 and lobular tumors and
no chemotherapy [59], the 10-year cumulative incidence of
death in the tamoxifen arm was 20%, similar to outcomes in
the tamoxifen arm of other AI trials in a higher-risk patient
population.
6.5 BIG 1-98: STA
Based on the early data, the design of BIG 1-98 was modified
early during the course of enrollment to allow for five
additional pairwise comparisons, with analyses commencing
at randomization [16]. The design was amended to address
the clinically relevant question of sequential therapy, and
although not a protocol-defined analysis, given the proven
superior efficacy of letrozole versus tamoxifen, two of the
pairwise comparisons were considered the most clinically
relevant and the focus of this analysis: sequential tamoxifen
to letrozole therapy versus letrozole monotherapy (N=
3,094), and sequential letrozole to tamoxifen therapy versus
letrozole monotherapy (N=3,086), with a median follow-up
of 71 months. It is important to distinguish the design of the
sequential therapy analysis (STA) from other trials, as it
allowed for the evaluation of sequential therapy versus
letrozole monotherapy in a double-blind manner, including
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previously investigated [16].
Results demonstrated that sequential therapy was not
superior to letrozole monotherapy. DFS (HR=1.05; 99%
CI, 0.84–1.32), OS (HR=1.13; 99% CI, 0.83–1.53), and
TTDR (HR=1.22; 99% CI, 0.88–1.69) favored letrozole
monotherapy over sequential therapy with tamoxifen then
letrozole. TTDR (HR=1.05; 99% CI, 0.75–1.47) favored
letrozole over letrozole followed by tamoxifen. Thus,
women who received sequential therapy in either order
were at greater risk for DM than those receiving mono-
therapy. Because BIG 1-98 was designed as superiority
trial, a lack of difference between groups cannot be inferred
as equivalence between treatments.
At 2 and 5 years, there were fewer breast cancer events in
the letrozole monotherapy group than in the tamoxifen to
letrozole group in both N+ patients (2 years: 4.7% vs. 7.9%;
5 years: 12.4% vs. 14.7%) and N− patients (2 years: 0.9% vs.
1.3%; 5 years: 3.5% vs. 4.9%). The number of breast cancer
events in the letrozole monotherapy group was similar to that
in the letrozole to tamoxifen group in N+ patients (2 years:
3.9% vs. 4.7%; 5 years: 12.4% vs. 12.5%), but there were
fewerbreastcancereventsintheletrozolemonotherapygroup
in N− patients (2 years: 0.9% vs. 1.5%; 5 years: 3.5% vs.
3.9%) [16]. These results suggest that adjuvant endocrine
therapy should begin with letrozole, unless contraindicated.
In addition, patients initiated on tamoxifen may be safely
switched to letrozole, if indicated (e.g., for SAEs).
6.6 TEAM: STA
Recently, results for the second of two co-primary
endpoints of the TEAM trial comparison of sequential
therapy versus exemestane monotherapy were reported
[40]. At a median follow-up of 5.1 years, and with 60%
of patients having completed 5 years of treatment, there
was no difference in efficacy between 5 years of upfront
exemestane compared with the sequence of tamoxifen to
exemestane. In the ITT analysis, there was no statistical
difference between the two arms in either DFS (HR=0.97;
95% CI, 0.88–1.08; P=0.604), TTR (HR=0.94; 95% CI,
0.83–1.06; P=0.293), or OS (HR=1.00; 95% CI, 0.89–
1.14; P=0.999). The investigators concluded that for PMW
with endocrine-sensitive early breast cancer, both
approaches are appropriate, and further translational
research in the trial population may identify patients who
could benefit more from one strategy over the other.
6.7 Effect on practice recommendations
In contrast to the 2007 St Gallen International Expert
Consensus, the 2009 panel preferred AIs as initial adjuvant
therapy, particularly in higher-risk patients [17]. In addition,
the IBCSG—based on updated results of BIG 1-98
demonstrating superior OS with letrozole versus tamoxi-
fen—now recommends starting adjuvant endocrine therapy
with letrozole, especially in patients at higher risk for early
recurrence [60]. If required, patients can be switched to
tamoxifen, but only after letrozole treatment for the first
2 years [60].
7 Extended AI therapy
7.1 Extended study design
In the extended adjuvant trial design, patients who received
the full course of adjuvant tamoxifen for 5 years and
showed no relapses or AEs during tamoxifen treatment
were randomized to receive further treatment with an AI or
a placebo.
7.2 MA.17: Extended therapy with letrozole
This double-blind, randomized, placebo-controlled trial ex-
amined the efficacy of letrozole as extended adjuvant therapy
in PMW (N=5,187) with HR+ or receptor status-unknown
disease after completing 4.5–6 years of upfront tamoxifen
[61]. At a median follow-up of 30 months, women treated
with letrozole had significantly better DFS (HR=0.58; P=
0.00004) and distant DFS (DDFS; HR=0.60; P=0.002)than
those treated with placebo. Although OS was not signifi-
cantly improved in the ITT population (HR=0.82; P=0.3),
OS was significantly better with letrozole in N+ patients
(HR=0.61; P=0.04) [44]. The highly significant DFS,
DDFS, and OS benefit led to unblinding of the trial
approximately 1 year earlier than planned, when 66% of
patients receiving placebo chose to switch to letrozole, while
34% elected no further treatment [62]. After a median
follow-up of 5.3 years, women who chose to switch to
letrozole demonstrated significant improvements in DFS
(HR=0.37; P<0.0001) and DDFS (HR=0.39; P=0.004)
compared with patients who chose to terminate treatment
[62]. Furthermore, examination of the outcomes of the trial
indicated that letrozole improves DFS and DDFS (61%
reduction in risk of metastasis) even when there has been a
substantial period of time (median, 2.8 years; range 1.1–
7.1 years) since the discontinuation of prior adjuvant therapy
[62]. These findings demonstrate that women who have
completed 5 years of adjuvant tamoxifen can benefit from
continuing treatment with letrozole, even if some time has
elapsed since discontinuing tamoxifen.
Interestingly, recent data on a subset of women in MA.17
(n=889) who were premenopausal when initially diagnosed
demonstrated that extended adjuvant therapy with letrozole
is significantly more effective in improving DFS in women
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(P=0.02) [63]. The benefit of letrozole was significantly
greater in premenopausal women (HR=0.25; 95% CI, 0.12–
0.51) than in postmenopausal women (HR=0.69; 95% CI,
0.52–0.91). Women who are premenopausal at the time of
diagnosis but become postmenopausal anytime before or
during adjuvant tamoxifen therapy should therefore be
considered for extended adjuvant therapy with letrozole.
7.3 ABCSG 6a: extended therapy with anastrozole
This open-label, non-controlled trial examined extended
adjuvant therapy in 856 HR+ PMW. Patients who completed
either 5 years of tamoxifen, or tamoxifen plus aminoglutethi-
mide for 2 years followed by tamoxifen monotherapy for
3 years, were randomized to either an additional 3 years of
anastrozole or no further treatment [45]. At a median follow-
up of 62.3 months, the risk of recurrence (local, contralateral,
or distant) was significantly reduced (HR=0.62; P=0.031),
as was the risk of DM (HR=0.53; P=0.034), in patients
treated with anastrozole compared with those receiving no
treatment, but no benefit was observed in OS (HR=0.89; P=
0.57) [45]. Although limited by its open-label design, the
results support the use of an AI in patients with a full course
of prior tamoxifen treatment.
7.4 NSABP B-33: extended therapy with exemestane
In this trial, ER+ PMW completing 5 years of tamoxifen were
randomized to receive exemestane or placebo for a further
5y e a r s[ 47]. When results from the MA.17 trial showed that
extended adjuvant therapy with letrozole after 5 years of
tamoxifen provided significant benefits, the B-33 trial was
closed prematurely, so that exemestane therapy could be
offered to patients receiving placebo. At the time of
unblinding, 1,598 patients had been randomly assigned;
72% in the exemestane group continued on exemestane, and
44% in the placebo group elected to receive exemestane. As
a result, the trial failed to reach its target accrual, and the
primary endpoint of the trial (DFS) did not reach signifi-
cance after a median follow-up of 30 months (relative risk
(RR)=0.68; P=0.07) [47]. A statistically significant im-
provement was only shown in the 4-year analysis RFS (96%
vs. 94%; RR=0.44; P=004). PMW with HR+ EBC continue
to be at risk of relapse and mortality after 5 years on
tamoxifen [64].
8 Meta-analysis of breast cancer outcomes in adjuvant
trials of AIs versus tamoxifen
The Aromatase Inhibitor Overview Group (AIOG) was
founded in December 2003 by the principal investigators of
all major AI clinical trials. Working in collaboration with
the EBCTCG, the AIOG sought to analyze the results of
almost 40,000 patients participating in AI trials of different
treatment strategies.
8.1 Upfront and switch therapy trials
A meta-analysis of randomized trials of monotherapy and
switching strategies presented during the 2008 San
Antonio Breast Cancer Symposium (SABCS) [65]w a s
r e c e n t l yp u b l i s h e db yt h eA I O G[ 66]. Data from random-
ized clinical trials comparing AIs with tamoxifen either as
initial monotherapy (cohort 1: ATAC and BIG 1-98/
IBCSG 18-98 trials) or after 2 to 3 years of tamoxifen
(cohort 2: German Adjuvant Breast Cancer Group/ARNO,
IES/BIG 2–97, ITA, and ABCSG 8 trials) were submitted
to the EBCTCG and used in separate meta-analyses of the
two cohorts. Primary analyses involved only PMW with
ER+ tumors. Cohort 1 included 9,856 patients with a
mean follow-up of 5.8 years. At 5 years, AI therapy was
associated with an absolute 2.9% (standard error (SE)=
0.7%) decrease in recurrence (9.6% for AI vs. 12.6% for
tamoxifen; 2P<0.00001) and a nonsignificant absolute
1.1% (SE=0.5%) decrease in breast cancer mortality
(4.8% for AI vs. 5.9% for tamoxifen; 2P=0.1). Cohort 2
included 9,015 patients with a mean follow-up of
3.9 years. At 3 years from switching treatment (approx-
imately 5 years after starting hormonal treatment), AI
therapy was associated with an absolute 3.1% (SE=0.6%)
decrease in recurrence (5.0% for AI vs. 8.1% for
tamoxifen since switch; 2P<0.00001) and an absolute
0.7% (SE=0.3%) decrease in breast cancer mortality
(1.7% for AI vs. 2.4% for tamoxifen since switch; 2P=
0.02). There was no apparent heterogeneity in the
proportional recurrence reduction with respect to age,
nodal status, tumor grade, or PgR, status and no indication
of an increase in non-breast cancer deaths with AIs in
either cohort. The absence of a statistically significant
difference in non-breast cancer death and overall mortality
in both cohorts was considered to be a possible indication
in favor of the overall safety of treatment with AIs. It was
concluded that AI-treated patients have statistically sig-
nificant improvements in RFS in both cohorts, and AIs
provide a significantly lower recurrence rate in both
upfront and switching strategies compared with tamoxifen
(23% and 40%, respectively). An OS benefit was only
seen in cohort 2 (patients who switched to AIs). The lack
of a significant difference in breast cancer mortality in
cohort 1 is probably time-dependent, and further follow-
up may be needed, given the experience with tamoxifen. It
is noteworthy that the above data cannot answer the
question whether the switching approach is better than the
upfront approach.
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A meta-analysis of extended AI therapy trials was presented
by the AIOG during the 2009 SABCS [67]. Included were
efficacy results from the MA.17, ABCSG 6a, NSABP B-33,
and Adjuvant post-Tamoxifen Exemestane versus Nothing
Applied (ATENA) trials. The ATENA trial was closed
prematurely—after only 448 of the planned 1,803 patients
had been enrolled—because of results of the MA.17 trial
[68]. Taken together, the extended AI therapy trials suggest
that continuing treatment with an AI after 5 years of
tamoxifen is better than no further treatment. However, this
has only been proven conclusively with letrozole [44–46, 62,
67]. The optimal duration of extended adjuvant therapy
remains undetermined.
9 Discussion
While the risk of recurrence may be greater for patients with
N+ status, all patients with EBC are at risk for recurrence,
including those with N− tumors of high grade or large size [4,
19]. Prognostic factors such as high Ki67 expression may
also identify a subgroup of patients (including those with N−
disease) at high risk for relapse and poor outcome [20].
Preventing DM is critical to improving outcomes; they
represent the majority of EBC recurrence events, which peak
approximately 2 years after surgery [4], and are associated
with the poorest prognosis compared with locoregional and
contralateral recurrences [5, 8, 10]. Therapies that effectively
reduce the risk of early DM are, therefore, likely to improve
long-term outcomes, including OS.
Major clinical trials clearly demonstrate a benefit of AI
therapy over tamoxifen in multiple adjuvant treatment
settings. In the initial adjuvant setting, both anastrozole
and letrozole have proven superior to tamoxifen in
improving DFS, whereas results for exemestane in this
setting remain inconclusive. In addition, initial adjuvant
letrozole has been shown to significantly reduce early DM
[6, 11]. This was also shown with anastrozole, but to a
significantly lesser extent [3, 48]. The significant reduction
in the incidence of early DM may in part explain the
emergent OS benefit with letrozole over tamoxifen with
long-term follow-up [16, 49], whereas no improvement in
survival has been seen for anastrozole over tamoxifen with
long-term follow-up [15]. Letrozole appears to be more
potent than anastrozole in terms of inhibiting estrogen [37,
69]. However, whether this results in differences in clinical
efficacy, remains to be determined in the directly compar-
ative FACE trial.
Adjuvant AI trials including the IES, ABCSG 8, and
ARNO 95 show that switching to an AI (anastrozole or
exemestane) after 2 to 3 years of tamoxifen is better than
continuing tamoxifen. However, it is not possible to
compare results from these switch trials with upfront trials,
because the switch trials included only patients who were
disease-free at the time of randomization. Recently reported
results from the STA of BIG 1-98 further suggest that using
a sequence of tamoxifen and letrozole, in either order, is not
superior to using letrozole monotherapy upfront [16], which
has already been shown to be better than tamoxifen
monotherapy. Exemestane was not shown to be better than
sequential therapy with tamoxifen and exemestane, but
exemestane also was not shown to be better than tamoxifen
in the upfront setting during the first 2.75 crucial years of
treatment [40]. Lastly, extended adjuvant trials have
demonstrated that continuing adjuvant endocrine therapy
with an AI improves outcomes when compared with no
further treatment in patients who have received the full
course of prior tamoxifen, although this benefit has been
conclusively shown only with letrozole.
10 Conclusions
Recent clinical trials have demonstrated the superiority of
initial treatment with AIs instead of tamoxifen, with
letrozole providing the most reduction in DM (30%) and
having the greatest impact on reducing the risk of early DM
[6, 11]. As reported by the updated analyses of BIG 1-98,
this is translating into an OS benefit with longer follow-up
[16, 49, 51]. A statistically significant effect of anastrozole
on reducing DM was observed only after a longer follow-
up (i.e., after 100 months), well beyond the crucial period
during which patients are at the highest risk of DM [15].
The STA of BIG 1-98 has shown that sequential therapy
with tamoxifen and letrozole, in either order, is not superior
to initial adjuvant letrozole [16], and recently published St.
Gallen guidelines seem to recommend the use of an AI
upfront, particularly in patients at higher risk of early
relapse [17]. However, for patients unable to begin adjuvant
e n d o c r i n et h e r a p yw i t ha nA I ,s w i t c ha n de x t e n d e d
adjuvant trials demonstrate that at the least, adding an AI
at some point after tamoxifen can help reduce the risk of
recurrence and improve outcome. While efforts to stratify
patients into prognostic subgroups are ongoing, it remains
difficult to quantify the risk of recurrence for an individual
patient. Until risk assessment strategies are more conclusively
validated in clinical trials, all patients should be considered
candidates for upfront AI treatment to effectively minimize
early DM and improve survival.
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